Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.

ABSTRACT: Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we compare the tumor immune landscape and peripheral T cell receptor (TCR) repertoire of patients with and without HRD-PCa to gain further insight into the immunogenicity of HRD-PCa. Immunohistochemistry was performed on tumor tissue of 81 patients, including 15 patients with HRD-PCa. Peripheral TCR sequencing was performed in a partially overlapping cohort of 48 patients, including 16 patients with HRD-PCa. HRD patients more frequently had intratumoral CD3⁺, CD3⁺CD8^-FoxP3^- or Foxp3⁺ TILs above

SUBMITTER: van Wilpe S 

PROVIDER: S-EPMC9255222 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature